BPG is committed to discovery and dissemination of knowledge
Review
©The Author(s) 2025.
World J Gastroenterol. Dec 14, 2025; 31(46): 114415
Published online Dec 14, 2025. doi: 10.3748/wjg.v31.i46.114415
Figure 4
Figure 4 Stem cell-based clinical trials for liver diseases. A: The categories of the registered stem cell-based clinical trials for liver diseases according to ClinicalTrial.gov; B-D: The status, clinical stage and location of the abovementioned stem cell-based clinical trials; E and F: The distribution of stem cell-based clinical trials for liver diseases according to the enrolled participants [enrollment (Log2N21)] and the corresponding cell types (N22) or the clinical trial number [condition (N23)]. BM-EPCs: Bone marrow-derived endothelial progenitor cells; LC: Liver cells; MSCs: Mesenchymal stem/stromal cells; hiPSCs: Human induced pluripotent stem cells; BM-MSCs: Bone marrow-derived mesenchymal stem/stromal cells; UC-MSCs: Umbilical cord-derived mesenchymal stem/stromal cells; ACLF: Acute-on-chronic liver failure; NASH: Non-alcoholic steatohepatitis.


Write to the Help Desk